The relationship between circulating fibrinogen and lipoprotein (a) levels in patients with primary dyslipidemia

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 1, 2007, Pages 35-42

  Ganotakis, Emmanuel S ^a,b   Gazi, Irene F ^a   Papadakis, John A ^b   Jagroop, I Anita ^a   Nair, Devaki R ^a   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cardiovascular risk; Dyslipidemia; Fibrinogen; Lipoprotein (a); Smoking

Indexed keywords

FIBRINOGEN; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; DYSLIPIDEMIAS; FEMALE; FIBRINOGEN; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; SMOKING;

EID: 33845398402     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606296256     Document Type: Article

References (78)

1. World Health Organization. The World Health Report [online]. Available from http://www.who.int/whr/2003/en/. Last accessed November 24, 2005.
2. Castelli WP, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986 ; 80: 23-32.
3. Assmann G, Schulte H, Cullen P. New and classical risk factors: the Munster heart study (PROCAM). Eur J Med Res. 1997 ; 2: 237-242.
4. Kannel WB. Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Am J Cardiol. 1996 ; 77: 6B - 11B.
5. Flack JM, Neaton J, Grimm R Jr, et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation. 1995 ; 92: 2437-2445.
6. Benderly M, Graff E, Reicher-Reiss H, et al. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscl Thromb Vasc Biol. 1996 ; 16: 351-356.
7. Breimer LH, Ganotakis ES, Mikhailidis DP. Fibrinogen as a cardiovascular risk factor. Rev Port Cardiol. 1997 ; 16: 245-250.
8. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993 ; 118: 956-963.
9. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996 ; 77: 1179-1184.
10. Dahlen G. H. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994 ; 108: 111-126.
11. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids. 2005 ; 40: 1210-1220.
12. de Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol. 2005 ; 12: 377-383.
13. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk. 1995 ; 2: 197-205.
14. Mikhailidis DP, Barradas MA, Maris A, Jeremy JY, Dandona P. Fibrinogen mediated activation of platelet aggregation and thomboxane A2 release: pathological implications in vascular disease. J Clin Pathol. 1985 ; 38: 1166-1171.
15. Papadakis JA, Jagroop IA, Ganotakis ES, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens. 1999 ; 12: 673-681.
16. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. Effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Des. 2003 ; 9: 2445-2465.
17. Papadakis JA, Mikhailidis DP, Vrentzos GE, Kalikaki A, Kazakou I, Ganotakis ES. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin Appl Thromb Hemost. 2005 ; 11: 139-146.
18. Jagroop IA, Papadakis JA, Mikhailidis DP. Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet function in essential hypertension. Platelets. 1998 ; 9: 395-396.
19. Nair DR, Papadakis JA, Jagroop IA, Mikhailidis DP, Winder AF. Statins and fibrinogen. Lancet. 1998 ; 351: 1430-1432.
20. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet. 1998 ; 351: 569-570.
21. Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int Angiol. 1998 ; 17: 225-233.
22. Rizos E, Bairaktari E, Ganotakis ES, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther. 2002 ; 7: 219-226.
23. Tanne D, Benderly M, Goldbourt U, et al, and the Bezafibrate Infarction Prevention Study Group. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the Bezafibrate Infarction Prevention Study. Am J Med. 2001 ; 111: 457-463.
24. Meade TW, for the British Medical Research Council General Practice Research Framework and participating vascular clinics. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease. Curr Control Trials Cardiovasc Med. 2001 ; 2: 195-204.
25. Kon Koh K, Yeal Ahn J, Hwan Han S, et al. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis. 2004 ; 174: 379-383.
26. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress and fibrinogen. Ann Intern Med. 1999 ; 131: 376-383.
27. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002 ; 18: 269-276.
28. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) levels in primary dyslipidaemia - a pilot study involving serial sampling. Curr Med Res Opin. 2001 ; 16: 269-275.
29. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003 ; 290: 932-940.
30. Enas EA, Chacko V, Senthilkumar A, et al. Elevated lipoprotein(a) - a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon. 2006 ; 52: 5-50.
31. Hoover-Plow J, Miles L, Fless G, et al. Comparison of the lysine binding functions of lipoprotein (a) and plasminogen. Biochemistry. 1993 ; 32: 13681-13687.
32. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989 ; 9: 579-583.
33. Warkentin TE. Hemostasis and atherosclerosis. Can J Cardiol. 1995 ; 11 (Suppl C). 29C - 35C.
34. Seed M, O'Connor B, Perombelon Y, et al. The effects of nicotinic acid and acipimox on serum lipoprotein (a) concentration and turnover. Atherosclerosis. 1993 ; 101: 61-68.
35. Espeland MA, Marcovina SM, Miller V, et al. Effects of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation. 1998 ; 97: 979-986.
36. Lee WY, Suh JY, Rhee EJ et al. Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lp(a) levels according to thyroid function status. Arch Med Res. 2004 ; 35: 540-545.
37. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated low-density lipoprotein cholesterol on the cardiovascular risk of lipoprotein (a). JAMA. 1997 ; 274: 1771-1774.
38. Heinrich J, Sandkamp M, Kokott R, et al. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 1991 ; 37: 1950-1954.
39. Slunga L, Asplund K, Johnson O, et al. Lipoprotein (a) in a randomly selected 25-64 year old population: the Northern Sweden Monica Study. J Clin Epidemiol. 1993 ; 46: 617-624.
40. Folsom AR, Qamhieh HT, Flack JM, et al. Plasma fibrinogen: levels and correlates in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol. 1993 ; 138: 1023-1036.
41. Cantin B, Despres JP, Lamarche B, et al. Association of fibrinogen and lipoprotein (a) as coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol. 2002 ; 89: 662-666.
42. Braeckman L, De Bacquer D, Rosseneu M, De Backer G. Determinants of lipoprotein (a) levels in a middle-aged working population. Eur Heart J. 1996 ; 17: 1808-1813.
43. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Heart Study. J Am Coll Cardiol. 1999 ; 33: 1347-1352.
44. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989 ; 10: 77-82.
45. Johansson J, Egberg N, Johnsson H, Carlson LA. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscl Thromb. 1993 ; 13: 1441-1448.
46. Cheng SW, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg. 1997 ; 14: 17-23.
47. Stone NJ. Secondary causes of hyperlipidaemia. Med Clin N Am. 1994 ; 78: 117-141.
48. Frati C, Bevilaqua L, Apostolico V. Association of etretinate and fish oil in psoriasis therapy. Inhibition of hypertriglyceridemia resulting from retinoid therapy after fish oil supplementation. Acta Dermato-Venereologica. 1994 ; 186 (Suppl). 151-153.
49. Mikhailidis DP, Spyropoulos KA. The effect of tamoxifen on lipid and haemostatic predictors of ischaemic heart disease. J Drug Dev Clin Pract. 1996 ; 8: 19-24.
50. Montgomery HE, Clarkson P, Nwose OM, et al. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. Arterioscl Thromb Vasc Biol. 1996 ; 16: 386-391.
51. Glueck CJ, Glueck HI, Tracy T, Speirs J, McCray C, Stroop D. et al. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism. 1993 ; 42: 236-246.
52. Iso H, Koike KA, Folsom AR, et al. Lipoprotein (a) and its correlates in Japanese and U.S. population samples. Ann Epidemiol. 1996 ; 6: 324-330.
53. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein (a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J. 1998 ; 19: 1355-1364.
54. Shai I, Rimm EB, Hankinson SE, et al. Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier? Eur Heart J. 2005 ; 26: 1633-1639.
55. Rosengren A, Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers. The study of men born in. 1933. J Intern Med. 1996 ; 239: 499-507.
56. Grines CL, Topol EJ, O'Neill WW, et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation. 1995 ; 91: 298-303.
57. Howard BV, Le NA, Belcher JD, et al. Concentrations of Lp(a) in black and white young adults: relations to risk factors for cardiovascular disease. Ann Epidemiol. 1994 ; 4: 341-350.
58. Schreiner PJ, Morrisett JD, Sharrett AR, et al. Lipoprotein (a) as a risk factor for pre-clinical atherosclerosis. Arterioscl Thromb Vasc Biol. 1993 ; 13: 826-833.
59. Catena C, Novello M, Lapenna R, et al. New factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). J Hypertens. 2005 ; 23: 1617-1631.
60. Iacoviello L, Vischetti M, Zito F, Benedetta Donati M. Genes encoding fibrinogen and cardiovascular risk. Hypertension. 2001 ; 38: 1199-1203.
61. de Maat MP. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann N Y Acad Sci. 2001 ; 936: 509-521.
62. Haines CJ, Chung TK, Masarei JR, Tomlinson B, Lau JT. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein (a) and other lipoproteins. Atherosclerosis. 1996 ; 119: 215-222.
63. Jatovic V, Kenemans P, Netelenbos JC, et al. Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein (a) concentrations in healthy postmenopausal women. J Clin Endocr Metabol. 1997 ; 82: 3543-3547.
64. Folsom AR. Epidemiology of fibrinogen. Eur Heart J. 1995 ; 16 (Suppl A). 21-23.
65. Dotevall A, Johansson S, Wilhelmsen L. Association between fibrinogen and other risk factors for cardiovascular disease in men and women. Results from the Goteborg MONICA survey. 1985. Ann Epidemiol. 1994 ; 4: 369-374.
66. Byrne DJ, Jagroop IA, Montgomery HE, et al. Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely any associated immediate cardiovascular risk. J Clin Phathol. 2002 ; 55: 280-285.
67. Kockx M, de Maat MP, Knipscheer HC, et al. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb Haemostas. 1997 ; 78: 1167-1172.
68. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996 ; 347: 849-853.
69. Goa KL, Barradell LB, Plosker GL. Bezafibrate: an update of its pharmacology and use in the management of dyslipidaemia. Drugs. 1996 ; 52: 725-753.
70. Ganotakis ES, Mikhailidis DP. Bezafibrate: treating hyperlipidemias as well as other cardiovascular risk factors. Today's Therap Trends. 1996 ; 13: 231-249.
71. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol. 2001 ; 87: 338-340.
72. Cantin B, Moorjani S, Dagenais GR, Lupien PJ. Lipoprotein (a) distribution in a French Canadian population and its relation to intermittent claudication (the Quebec Cardiovascular Study). Am J Cardiol. 1995 ; 75: 1224-1228.
73. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation. 1995 ; 91: 948-950.
74. Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med. 1994 ; 154: 801-806.
75. Willeit J, Kiechl S, Santer P, et al. Lipoprotein (a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study. Stroke. 1995 ; 261: 582-587.
76. Barasch E, Benderly M, Graff E, et al. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. J Clin Epidemiol. 1995 ; 48: 757-765.
77. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscl Thromb Vasc Biol. 1995 ; 15: 1263-1268.
78. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995 ; 332: 635-641.